Skip to main content
MediciNova,Inc. logo

MediciNova,Inc. — Investor Relations & Filings

Ticker · 4875 ISIN · US58468P2065 T Manufacturing
Open in API
Filings indexed 60 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country JP Japan
Listing T 4875

About MediciNova,Inc.

https://medicinova.com/

MediciNova, Inc. is a clinical-stage biopharmaceutical company that acquires and develops novel, small-molecule therapeutics. The company's late-stage pipeline focuses on addressing unmet medical needs in neurology, respiratory, and liver diseases. Key development programs include MN-166 (ibudilast) for neurological conditions, MN-001 (tipelukast) for fibrotic diseases such as liver fibrosis (NASH) and pulmonary fibrosis (IPF), and MN-221 for respiratory conditions including acute exacerbations of asthma and COPD.

Recent filings

Filing Released Lang Actions
米国におけるMN-166（イブジラスト）の免疫チェックポイント阻害剤PD-1抗体との併用療法による膠芽腫治療を対象とする特許承認に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing that MediciNova has received approval for a patent relating to its MN-166 drug in the United States. It does not present financial statements, earnings, governance materials, management changes, or meeting results. It is not a regular report (Annual, Interim, ESG, etc.) but rather a regulatory announcement about patent approval. Therefore, it falls under the general "Regulatory Filings" category (RNS).
2026-06-08 Japanese
MN-001（タイペルカスト）の2型糖尿病に起因する高中性脂肪血症及び脂肪肝疾患に関するフェーズ2臨床試験の最終患者最終来院完了に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a press release announcing the completion of the Last Patient Last Visit of a Phase 2 clinical trial for MediciNova’s drug candidate. It contains no financial statements, no shareholder vote, no management changes, and no earnings data. It does not constitute an annual or interim report, earnings release, investor presentation, or any of the specific categories (e.g., M&A, dividend notice, share issue). It is a general company announcement filed under regulatory news. Therefore, by elimination it best fits the "Regulatory Filings" fallback category (RNS).
2026-05-27 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act of Japan. It serves as an officer certification confirming the accuracy of a previously filed semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS). H1 2025
2025-09-12 Japanese
半期報告書
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by MediciNova, Inc. with the Kanto Local Finance Bureau in Japan. It contains detailed financial data, including balance sheets, income statements, and cash flow statements for the interim period ending June 30, 2025. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-12 Japanese
臨時報告書
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director on June 25, 2025. Section 1, '提出理由' (Reason for Submission), explicitly states that the report is being filed based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the company's Annual General Meeting (AGM) held on June 17, 2025. Section 2 details the resolutions passed, including the election of a director and the approval of the independent registered accounting firm, along with the voting results (votes for, against, abstentions). This content perfectly matches the description of reporting the results of a shareholder vote following a general meeting. The most specific code for reporting official results from shareholder votes at any general meeting is DVA (Declaration of Voting Results & Voting Rights Announcements). Although it relates to an AGM, the core content is the voting outcome declaration, not the AGM presentation materials (AGM-R) or the proxy solicitation materials (PSI).
2025-06-25 Japanese
内部統制報告書
Audit Report / Information Classification · 100% confidence The document contains a 'Report of Independent Registered Public Accounting Firm' which explicitly states an 'Opinion on Internal Control over Financial Reporting' as of December 31, 2024, based on COSO criteria. It also includes a section titled '内部統制報告書' (Internal Control Report) detailing the basis for evaluation, scope, and the conclusion that internal controls over financial reporting were effective as of the year-end date. This structure—an auditor's opinion on internal controls combined with the management's internal control report—is characteristic of the documentation required for the annual filing concerning internal controls, which often accompanies the 10-K or is filed separately as an Audit Report/Information, especially when it focuses specifically on the audit of internal controls rather than the full financial statements themselves. Since the primary focus here is the formal opinion and report on the effectiveness of internal controls over financial reporting, the most fitting category is 'Audit Report / Information' (AR), as it is a standalone audit report focusing on controls, distinct from the comprehensive 10-K or a simple Earnings Release (ER). The presence of the auditor's report and the explicit reference to internal control testing strongly supports AR. FY 2024
2025-06-10 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.